ClinicalTrials.gg
Active, not recruitingNCT07240558PIVOTUpdated Oct 23, 2026

Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)

A Phase 3 interventional study of H5N1 vaccine (Arepanrix, GSK) and Placebo in Influenza (Pandemic), Avian Influenza and Vaccination, sponsored by University Health Network, Toronto. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by University Health Network, Toronto · Phase 3, Interventional, and Prevention

How we know

Updated Oct 23, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 157 studies in Influenza, Human with a site in Canada — 7 open to participants now, 12 under way, 4 of them phase 3. Influenza, Human · Canada.

Planned enrollment
93rd of 131
120 · median 300
Started
2025
with 1 other
Phase 3
42 of 157
3 open now
Primary completion
2027-04
later than 6 of 11 live
Registered
153rd of 157
by date
Lead sponsor
6 of 157
University Health Network, Toronto

Among the 157 studies in Influenza, Human with a site in Canada, this one is the 93rd largest by planned enrollment of the 131 interventional ones that give a count, is one of 2 that started in 2025, is one of 42 in phase 3, reaches primary completion later than 6 of the 11 other live ones, and was the 153rd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 157 studies in Influenza, Human with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies in Influenza, Human with a site in Canada, or all of them as a file.
02

Study summary

Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the next influenza pandemic may be soon approaching. Transplant patients will likely be uniquely predisposed to serious infection with high morbidity and mortality. There are a number of important reasons that evaluation of prevention strategies are critical in this highly vulnerable population. Currently, there is no data on the immunogenicity of H5Nx vaccines in this highly vulnerable population. The investigators plan to study the safety and immunogenicity of a two-dose regimen of the pandemic influenza H5N1 vaccine in organ transplant patients.

Read the detailed description

This randomized, placebo-controlled, double-blind, single-centre trial will evaluate the immunogenicity and safety of a two-dose regimen of the AS03-adjuvanted inactivated H5N1 vaccine (AREPANRIX™ H5N1, GSK) in adult organ transplant recipients. A total of 120 stable outpatient organ transplant recipients at the University Health Network (Toronto, Canada) will be enrolled and randomized 1:1 to receive two doses of H5N1 vaccine or placebo (0.9% saline) administered intramuscularly 3 weeks apart.

Blood samples collected at baseline (V0), 3 weeks (V1), and 6 weeks (V2) will be analyzed for serologic responses using hemagglutination inhibition (HAI) assays against vaccine and circulating H5N1 strains. In a subset of 60 participants (30 per arm), peripheral blood mononuclear cells will be obtained at each time point to assess cell-mediated immunity, including H5-specific CD4+ and CD8+ T-cell cytokine responses and B-cell immunity.

Participants will be monitored for local and systemic adverse events for 7 days following each dose and followed for 6 months for any adverse events, including rejection, influenza-like illness, and laboratory-confirmed influenza. Long-term immunogenicity will also be assessed at 6 months in vaccine recipients.

03

Conditions studied

  • Influenza (Pandemic)
  • Avian Influenza
  • Vaccination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 and greater than 3 months post-transplant
  • Stable graft function
  • >30mL/min/1.73m2
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Allergy to vaccine components;
  • Previous life-threatening reaction to influenza vaccine (ie Guillain Barré Syndrome);
  • Ongoing or recent therapy for acute rejection (within the previous 30 days);
  • Ongoing active cytomegalovirus (CMV) infection with viral load of greater or equal to 1000 international units/ml in the last 7 days;
  • Febrile illness in the past 2 weeks;
  • Rituximab in the last 6 months;
  • Receiving treatment for active or acute infection;
  • Unable to provide ;
  • 2025 seasonal influenza vaccination in preceding 6 weeks;
  • Recent other vaccination in last 14 days;
  • Receipt of intravenous immunoglobulin in last 30 days or expected to receive in next 30 days; \< 3 months;
  • Diagnosis of influenza virus infection in the last 90 days.
  • Pregnancy known at the time of enrolment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    H5N1 vaccine

    This arm will receive 2 doses of approved H5N1 vaccine, 3 weeks apart

    Biological: H5N1 vaccine (Arepanrix, GSK)

  • Placebo comparator
    Placebo

    This arm will receive 2 doses of normal saline (placebo), 3 weeks apart

    Biological: Placebo

Interventions

  • BiologicalH5N1 vaccine (Arepanrix, GSK)

    2 doses of H5N1 vaccine, 3 weeks apart, given IM (deltoid)

  • BiologicalPlacebo

    2 doses of 0.5mls normal saline, 3 weeks apart, given IM (deltoid)

06

What researchers measure

Primary outcomes

  1. Seroprotection and seroconversion 6 weeks after dose 1

    Participants with seroprotection (HAI titers greater than or equal to 1:40) after dose 2 AND seroconversion, defined as greater than or equal to 4-fold increase in HAI antibody titers from baseline to after dose 2 to the vaccine-matched H5 avian influenza strain.

    Time frame: 6 weeks after dose 1 and 3 weeks after dose 2

Secondary outcomes

  1. Seroprotection and seroconversion after dose 1 and comparison with after dose 2

    Time frame: 6 weeks after dose 1

  2. T and B cell immunity after dose 1 and dose of vaccine

    Time frame: 3 and 6 weeks post dose 1

  3. Durability of immunity at 6 months post dose 1

    Time frame: 6 months post dose 1

  4. Local and systemic adverse events to vaccination

    Time frame: Until 6 months post dose 2

  5. Other safety factors

    Transplant rejection, influenza like illness, confirmed influenza episodes

    Time frame: Until 6 months post dose 2

  6. Seroprotection and seroconversion after dose 1 and 2 to H5, H1, H3

    Time frame: 6 weeks and 3 weeks post dose 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Deidentified aggregated data will only be shared with appropriate request and ethical approval.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

Of 35 non-industry phase 3 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's planned 17 months is close to that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jun 2026 → Apr 2027 and completion Dec 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 21, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Apr 30, 2027was Jun 2026
CompletionEst.
Apr 30, 2027was Dec 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 23, 2026
Primary completion
Jun 30, 2026→Apr 30, 2027
Oct 23, 2026
Study completion
Dec 31, 2026→Apr 30, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 30, 2026→Apr 30, 2027
    Study completion Dec 31, 2026→Apr 30, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07240558
Collaborators
Laval University
Responsible party
Victoria Hall (Dr Victoria Hall, Principal Investigator, Clinician-Investigator and Infectious Diseases physician, University Health Network, Toronto) — Principal investigator
First posted
Nov 21, 2025
Start date
Nov 3, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion